Matthew Calistri | Vice President of Investor Relations |
Ron Renaud | President and Chief Executive Officer |
Raymond Sanchez | Chief Medical Officer |
John Renger | Chief Scientific Officer |
Susan Altschuller | Interim Chief Financial Officer |
Michael DiFiore | Evercore ISI |
Mohit Bansal | Wells Fargo |
Graig Suvannavejh | Mizuho Securities |
Tazeen Ahmad | Bank of America |
Paul Matteis | Stifel |
Joseph Thome | TD Cowen |
Jeff Hung | Morgan Stanley |
Michael Yee | Jefferies |
Charles Duncan | Cantor Fitzgerald |
Douglas Tsao | H.C. Wainwright |
Good morning and welcome to Cerevel Therapeutics Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded.
I will now hand the call over to Matt Calistri, Vice President of Investor Relations.